Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
bioAffinity Technologies, Inc. ( (BIAF) ) has issued an update.
On October 16, 2025, bioAffinity Technologies, Inc. announced it received a notification of allowance from the United States Patent and Trademark Office for a patent titled ‘Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.’ This patent covers a system and method for predicting lung cancer by analyzing patient sputum samples using an AI-built algorithm and flow cytometry platform. This development enhances bioAffinity’s intellectual property portfolio, which includes 18 awarded and 33 pending patents globally, and reinforces its position in the early-stage cancer diagnostics industry. The CyPath® Lung test, integral to this patent, offers high sensitivity and specificity in detecting early-stage lung cancer, potentially improving patient outcomes and reducing healthcare costs.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is primarily driven by the company’s weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on advancing early-stage cancer diagnostics and broad-spectrum cancer treatments. Their primary product, CyPath® Lung, is a noninvasive test for early-stage lung cancer, marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 2,451,590
Technical Sentiment Signal: Sell
Current Market Cap: $12.19M
See more data about BIAF stock on TipRanks’ Stock Analysis page.